Genmab — Februar 2016
-
Sikken et første halvår vi får.
-
ofa superior i rrms
-
lavere toxicitet og sc admininstration
-
1000s of patients in Novartis trial
-
ofa FL milstone er nu usd 80 (pga valuta) og udløses af approval
-
derfor ingenting i 2016
-
castor pollux - pfs er primary også for interim.
-
Skal se på considerable improvement in pfs over control arm - and can look at other trials for comparison
-
lyder ikke som om der er meget tvivl om dara. Og et pikant prik til Carsten fra SEB
-
10 IND kandidater for de næste 4 år
-
acceleration fase in 2018-19 will also include immunoincology
-
half of development
programs are immunoncology -
Jan on FIRE
-
tiso likely gonna be shared with SGEN
-
den var ny!!!
-
Helt ny!
-
-
haha
-
Godt CC
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind